glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Comparison of agonists inhibitors DPP-4 inhibitors and GLP-1RAs: cardiovascular

ja.ma/43dttwm #GLP-1 receptor agonists show evidence of reducing #Psoriasis severity and systemic inflammation in patients with #obesity or #diabetes, with a favorable safety profile and compatibility with standard therapies

2018;72:e13055

RR, risk ratio

A statistical analysis assimilated various studies which insisted that GLP-1 agonists play a pivotal role in regulating menstrual cycle, ameliorating pregnancy rates and addressing infertility, a key concern in PCOS, though these benefits appeared to be temporary as drugs were only prescribed for 12 weeks and IVF pregnancies were unaffected

The subsequent phase 3 trial of tirzepatide demonstrated more effective reductions in the glycated hemoglobin levels and body weight, along with greater overall improvements in the lipid profile compared to semaglutide in patients with T2DM, elevating incretin therapeutic agents to a new level (112)